Enhertu (trastuzumab deruxtecan), an antibody-drug conjugate drug used to treat certain types of breast cancer, has been turned down for English funding in a new indication after the country’s health technology assessment (HTA) body NICE said its co-developers were “unwilling” to offer the drug at a lower price.
The indication for which NICE rejected the reimbursement of Enhertu was HER2-low metastatic breast cancer. It is already available for NHS patients in England with certain forms of HER2-positive breast cancer via the Cancer Drugs Fund, an interim funding mechanism that provides patient access to cancer medicines while evidence is collected on their clinical effectiveness